Biogen pivots to second amyloid-targeted Alzheimer's drug with accelerated approval filing from partner Eisai
Almost exactly a year ago, Biogen CEO Michel Vounatsos boasted that the company’s new Alzheimer’s drug, prepping for billions in sales following its quick FDA approval, was a “first-in-class medicine” that “will transform the treatment of people living with Alzheimer’s disease.”
One year later and Aduhelm has been used in very few patients, Eisai has basically dropped its involvement, and now the drug has been all but completely discarded by Biogen as the company is under at least a half dozen investigations from the FDA, HHS, SEC, FTC and congressional committees related to its close links with the FDA and how it won approval.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.